DEFA14A ·Filed Apr 24, 2026
Proxy solicitation materials
Actionable Insight • Neutral
Monitor for any changes in board composition or executive compensation following the vote, as the recent CFO resignation may signal underlying governance issues.
Final — all horizons settled through T+60d
KLRS ▼ -32.39% at T+60d
NEUTRAL call -32.39% · α vs SPY -37.17% · entry $6.02 → $4.07
T+1d
-6.40%
call -6.40% · α -5.91%
$5.64
settled 6mo ago
T+5d
-8.14%
call -8.14% · α -8.54%
$5.53
settled 6mo ago
T+20d
-13.46%
call -13.46% · α -18.41%
$5.21
settled 5mo ago
T+60d
-32.39%
call -32.39% · α -37.17%
$4.07
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Kalaris Therapeutics is holding its 2026 annual meeting to vote on the election of three Class III directors, approval of executive compensation, frequency of future compensation votes, and ratification of its auditor. This filing is routine, but follows a recent CFO resignation, suggesting potential board-level instability.
Key Financial Metrics
Vote
director election
Meeting
2026-06-03
Key Facts
- Annual meeting scheduled for June 3, 2026.
- Shareholders will vote on the election of three Class III directors: Napoleone Ferrara, M.D., David Hallal, and Leone Patterson.
- Shareholders will vote on the approval of executive compensation.
- Shareholders will vote on the frequency of future executive compensation votes.
- Shareholders will vote on the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for 2026.
- The board recommends a vote FOR all proposals.
- This filing follows the April 10, 2026, resignation of CFO Matthew Gall.
Financial Impact
No direct financial impact.
Risk Factors
- Potential for shareholder dissatisfaction with executive compensation.
- Board instability following the CFO resignation.
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (12 analysts)
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-177383 |
| Document: 0001193125-26-177383-index-headers.html | 0001193125-26-177383 |
| Document: 0001193125-26-177383-index.html | 0001193125-26-177383 |
| Document: 0001193125-26-177383.txt | 0001193125-26-177383 |
16 reports for KLRS
40% Hit rate @ T+60 Went positive at some point 2 of 5 best @ T+60▲ +27.75%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13G | $1.80 | awaiting T+60 | — | $1.86 (+3.33%) |
Aug 11, 2026 11w ago | 8-K | $3.97 | awaiting T+60 | — | $1.86 (−53.15%) |
Aug 11, 2026 11w ago | Press Release | $3.97 | awaiting T+60 | — | $1.86 (−53.15%) |
Aug 3, 2026 12w ago | 3 | $4.32 | awaiting T+60 | — | $1.86 (−56.94%) |
Jul 20, 2026 14w ago | 8-K | $4.00 $2.23 | ▼ −44.25% | ▼ −49.09% | $1.86 (−53.50%) |
Jul 17, 2026 14w ago | 8-K | $4.38 $2.26 | ▼ −48.40% | ▼ −53.09% | $1.86 (−57.53%) |
Jul 17, 2026 14w ago | Press Release | $4.38 $2.26 | ▼ −48.40% | ▼ −53.09% | $1.86 (−57.53%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.36 $3.90 | ▼ −10.55% | ▼ −14.95% | $1.86 (−57.34%) |
May 12, 2026 24w ago | 8-K | $4.79 $4.19 | ▼ −12.53% | ▼ −16.91% | $1.86 (−61.17%) |
May 12, 2026 24w ago | Press Release | $4.79 $4.19 | ▼ −12.53% | ▼ −16.91% | $1.86 (−61.17%) |
Showing 10 of 16
US Market Status
Market Closed — Opens Wed (17h 17m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers